iShares Core High Dividend ETF vs Hims and Hers Health Inc — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.72B), while Hims and Hers Health Inc trades at $28.44 (market cap $6.89B). The key difference: iShares Core High Dividend ETF is far larger — about 2.1× Hims and Hers Health Inc's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Hims and Hers Health Inc for 21 Days on average.
| HDV | HIMS | |
|---|---|---|
Market Cap | $14.72B | $6.89B |
Volume | 2,297,177 | 5,446,628 |
52-Week High | $29.93 | $62.76 |
52-Week Low | $23.64 | $14.52 |
Typical Hold Time | 117 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $7.60B |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% with neutral technical signals. The ETF recently underwent significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. Technical indicators show mixed signals with bearish moving averages but neutral oscillators. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the fund's 3% yield may not fully compensate for increased concentration risks.
The outlook remains cautious as HDV's sector concentration (62% in three sectors) creates heightened risk exposure. While the dividend yield provides income stability, the fund's recent underperformance relative to peers and reduced diversification warrant careful monitoring. Investors should weigh the trade-off between current income and long-term growth potential given the significant portfolio restructuring.
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →